Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(0.43) per share. This is a 49.41 percent increase over losses of $(0.85) per share from the same period last year.
Brii Biosciences Agrees To Acquire VBI’s IP Rights In BRII-179 (VBI-2601) And Plans To Initiate Technology Transfer To Expand Clinical And Commercial Supplies
Under these agreements, Brii Bio will issue a $2.5 million promissory note to VBI initially. This will eliminate royalty and milestone payments for PreHevbri. Upon meeting specific conditions, the
